首页> 外文OA文献 >Sensitivity of NS3 Serine Proteases from Hepatitis C Virus Genotypes 2 and 3 to the Inhibitor BILN 2061
【2h】

Sensitivity of NS3 Serine Proteases from Hepatitis C Virus Genotypes 2 and 3 to the Inhibitor BILN 2061

机译:丙型肝炎病毒基因型2和3的NS3丝氨酸蛋白酶对抑制剂BILN 2061的敏感性

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Hepatitis C virus (HCV) displays a high degree of genetic variability. Six genotypes and more than 50 subtypes have been identified to date. In this report, kinetic profiles were determined for NS3 proteases of genotypes 1a, 1b, 2ac, 2b, and 3a, revealing no major differences in activity. In vitro sensitivity studies with BILN 2061 showed a decrease in affinity for proteases of genotypes 2 and 3 (Ki, 80 to 90 nM) compared to genotype 1 enzymes (Ki, 1.5 nM). To understand the reduced sensitivity of genotypes 2 and 3 to BILN 2061, active-site residues in the proximity of the inhibitor binding site were replaced in the genotype-1b enzyme with the corresponding genotype-2b or -3a residues. The replacement of five residues at positions 78, 79, 80, 122, and 132 accounted for most of the reduced sensitivity of genotype 2b, while replacement of residue 168 alone could account for the reduced sensitivity of genotype 3a. BILN 2061 remains a potent inhibitor of these non-genotype-1 NS3-NS4A proteins, with Ki values below 100 nM. This in vitro potency, in conjunction with the good pharmacokinetic data reported for humans, suggests that there is potential for BILN 2061 as an antiviral agent for individuals infected with non-genotype-1 HCV.
机译:丙型肝炎病毒(HCV)表现出高度的遗传变异性。迄今已鉴定出六种基因型和50多种亚型。在此报告中,确定了基因型1a,1b,2ac,2b和3a的NS3蛋白酶的动力学曲线,显示活性没有重大差异。使用BILN 2061进行的体外敏感性研究表明,与基因型1的酶(Ki,1.5 nM)相比,对基因型2和3(Ki,80至90 nM)的蛋白酶的亲和力降低。为了理解基因型2和3对BILN 2061的敏感性降低,在抑制剂结合位点附近的活性位点残基在基因型1b酶中被相应的基因型2b或-3a残基取代。在78、79、80、122和132位取代五个残基是造成基因型2b敏感性降低的主要原因,而仅置换168个残基可能会导致基因型3a敏感性降低。 BILN 2061仍然是这些非基因型1 NS3-NS4A蛋白的有效抑制剂,Ki值低于100 nM。这种体外效力,再加上针对人类报道的良好药代动力学数据,表明BILN 2061有潜力作为感染非基因1型HCV的个体的抗病毒剂。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号